MSK: Giant Cell Tumor: Free MSRA Podcast

🎧MSRA Deep Dive: GiantCell Tumour of Bone — Benign but Not HarmlessEver heard of atumour that’s technically benign… but still packs a punch? Welcome to thisfocused, high-yield episode on Giant Cell Tumour(GCT) — a locally aggressive bone tumourthat’s vital to understand for MSRA success. 🦴What is a Giant CellTumour (GCT)?A rare, primary bone tumourTypically benign, but locally aggressiveMost commonly found at the epiphysis of long bones, especially around the knee (distal femur, proximal tibia)Microscopically: Multinucleated giant cells + mononuclear stromal cells 🔍Cause & RiskFactorsExact cause unknownGenetic mutation: H3F3A mutation often presentNot inheritedOccasionally associated with Paget's disease or enchondromatosisNo consistent lifestyle or environmental risk factors 📊EpidemiologyRoughly 5% of all primary bone tumoursAffects mainly young adults (20–40 years)Slight female predominance 🧠Mnemonic forDifferentials – OCABO: OsteosarcomaC: ChondroblastomaA: Aneurysmal bone cyst (ABC)B: Brown tumour (hyperparathyroidism) 🧬PathophysiologyStromal cells proliferate, activating osteoclast-like giant cellsThese giant cells resorb bone → leads to local destructionOften affects subarticular regions, close to jointsMay cause pathological fractures 🧾Clinical Features –PSPP: Pain over the affected areaS: Swelling and local tendernessP: Poor joint motion (if periarticular)Risk of fracture with minimal traumaSometimes incidental finding on imaging 🧪DiagnosisX-ray: Lytic, expansile lesion in epiphyseal/metaphyseal regionMRI or CT: For assessing extent, cortical breachBiopsy: Essential for definitive diagnosisMolecular testing: May detect H3F3A mutation 🩺Management (UK)🛠️ Surgical Curettage + Adjuvants:Bone cement (thermal necrosis of residual cells)Cryotherapy🧬 Denosumab:A RANKL inhibitorUsed pre-op, post-op, or non-surgical cases🦿 En bloc resection: For recurrent/extensive tumours🏥 Joint reconstruction may be needed post-resection 📈Prognosis &RecurrenceGenerally good, but recurrence is common20–40% recurrence rateRare risk of malignant transformation into sarcomaLifelong follow-up often advised ⚠️ComplicationsLocal recurrencePathological fracturesJoint dysfunctionMalignant transformation (rare) 📚MSRA Revision NuggetsBenign doesn’t mean non-destructiveThink PSP: pain, swelling, poor motionKnow your OCAB differentialsSurgery = cornerstone of treatmentDenosumab targets osteoclast pathwayRecurrence? Think 1 in 3 casesAlways assess for risk of fracture or joint compromise 🔗Resources to SupportYour Revision📝 Revision Notes:https://www.passthemsra.com/topic/giant-cell-tumour-revision-notes/🃏 Flashcards:https://www.passthemsra.com/topic/giant-cell-tumour-flashcards/📖 Accordion Q&A Notes:https://www.passthemsra.com/topic/giant-cell-tumour-accordion-qa-notes/🎯 Rapid Quiz:https://www.passthemsra.com/topic/giant-cell-tumour-rapid-quiz/🧠 Quiz Link:https://www.passthemsra.com/quizzes/giant-cell-tumour/ 🌐Explore More MSRAResourceshttps://www.passthemsra.comhttps://www.freemsra.com#MSRA#GiantCellTumour #MSRARevision #MSRAFlashcards #MSRAQuiz #OrthopaedicsMSRA#BoneTumours #MSK #MSRAHighYield #PassTheMSRA #FreeMSRA#MultinucleatedGiantCells #Orthopaedics